H6H
UTHR icon

Hightower 6M Holding’s United Therapeutics UTHR Stock Holding History

Hightower 6M Holding’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,024
Closed -$241K – 353
2022
Q2 		$241K Buy
+1,024
New +$208K 0.02% 214

Other funds holding UTHR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Hightower 6M Holding's UTHR Position: Q3 2022 in Review

Hightower 6M Holding sold out of United Therapeutics (UTHR) in Q3 2022, closing a stake of 1,024 shares — an estimated $241K sold.

Hightower 6M Holding first reported a position in UTHR in Q2 2022 and held it in 1 quarter. The position peaked at $241K in Q2 2022. 461 funds tracked by Wall St. Rank hold UTHR as of Q3 2022.

  • Hightower 6M Holding reported no remaining United Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Hightower 6M Holding sold 1,024 United Therapeutics shares in Q3 2022, an estimated $241K.
  • Hightower 6M Holding first reported a position in United Therapeutics in Q2 2022 and held it in 1 quarter.
  • Hightower 6M Holding's United Therapeutics position peaked at $241K in Q2 2022.
  • 461 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2022.

Based on Hightower 6M Holding's 13F filing for Q3 2022, filed 25 Oct 2022.